menu
    • menu
    [{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tegafur","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"Folic acid","graph1":"Immunology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cross-linked Hyaluronic Acid","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Pharma

    Menu

    Nordic Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cross-linked Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Pharma to Present Data on LACRIFILL® Gel for Dry Eye at Refractive Surgery Meeting

                            Details : LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

                            Brand Name : Lacrifill

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 02, 2024

                            Lead Product(s) : Cross-linked Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Pharma Files Submission to Health Canada for The Marketing Authorization of Methotrexate Autoinjector f...

                            Details : Methotrexate is considered a cornerstone therapy for patients with rheumatoid arthritis (RA), with well-established safety and efficacy profiles and support in international guidelines.

                            Brand Name : Nordimet

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2022

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Pharma

                            France arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur,Gimeracil,Oteracil

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer

                            Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.

                            Brand Name : Teysuno

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2022

                            Lead Product(s) : Tegafur,Gimeracil,Oteracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth